Paving a New Path for Precision Cardiology
Our vision is to pioneer precision RNA medicines for the heart and profoundly improve the lives of people impacted by cardiac diseases.
Delivering on the RNA Revolution
Our novel RNA delivery platform, built on the clinically validated AOC technology originally designed at Avidity Biosciences, is uniquely capable of delivering RNA directly to the heart muscle. By combining the specificity of mAbs with the precision of oligonucleotide therapies, our groundbreaking technology circumvents critical challenges with cytotoxicity, immunogenicity, and limitations on redosing that other delivery systems are constrained by.
Our pipeline includes two lead development candidates – ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome and ATR 1086 for PLN (phospholamban) cardiomyopathy. The company has two additional undisclosed research stage targets in rare cardiomyopathies. We plan to file an IND for ATR 1072 in the second half of 2026.
Pioneering a New Frontier for Cardiac Patients
Approximately two million people in the US have been diagnosed with a cardiomyopathy, and nearly 50% of those have an underlying genetic driver of the disease1,2,3. Despite the prevalence of heart disease, the standard of care for patients suffering from rare cardiomyopathies consists of symptom management and invasive procedures such as pacemakers, implantable cardioverter defibrillators (ICD), or even heart transplants4.
At Atrium Therapeutics, we believe delivering precision RNA therapeutics to the heart is the next frontier in transforming care for patients living with cardiac disease. Our initial focus is a pair of life-threatening cardiomyopathies with no approved treatment options and high unmet need: PLN (Phospholamban) cardiomyopathy and PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) Syndrome.
1 Kramer,C. Et al, “Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy. Am Heart J. 2015 Aug;170(2):223-30 and Ababio, Yaa et al, “Prevalence and Clinical Burdenof Idiopathic Dilated Cardiomyopathy in the United States”. Am J of Medicine Open Volume 10, 2023.
2 Ho, CY. “Genotype and lifetime burden of disease in hyptertrophic cardiomyopathy
3 Cheng, Z,. et al, “Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment”. Frontiers in Cardiovascular Medicine vol. 8 (2021). DOI=10.3389/fcvm.2021.722340
4 Hutt, E, et al, “Medical Treatment Strategies for Hypertrophic Cardiomyopathy.” American Journal of Cardiology vol 212, S33-41
Who we are
Meet the Team
Atrium Therapeutics was founded to redefine standard of care paradigms for patients living with heart disease by addressing the underlying causes of cardiomyopathies. Our proprietary RNA delivery platform unlocks the next generation of precision cardiology possibilities by uniquely delivering therapeutics directly into heart tissue.
Our team has extensive experience in successfully developing and commercializing RNA therapies at major pharmaceutical and biotechnology companies. We have deep rare disease expertise from drug development through commercial activities including working with regulatory agencies and engaging with patient communities. Under the leadership of our CEO, Kath Gallagher, we are committed to making a difference for patients by pioneering the delivery of RNA-based precision cardiology therapeutics directly to the heart muscle.
The Latest
Featured News
Press Release
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Atrium Therapeutics, Inc. (Nasdaq: RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart.